Landos Biopharma (LABP) News Today Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period May 24, 2024 | marketbeat.comLandos Biopharma (NASDAQ:LABP) Trading Up 0.6%Landos Biopharma (NASDAQ:LABP) Trading Up 0.6%May 23, 2024 | prnewswire.comAbbVie Completes Acquisition of Landos BiopharmaMay 11, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMay 9, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024April 26, 2024 | msn.comEx-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookApril 17, 2024 | msn.comLandos Biopharma (LABP) Price Target Increased by 154.20% to 12.96April 16, 2024 | prnewswire.comStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieApril 10, 2024 | marketbeat.comLandos Biopharma, Inc. (NASDAQ:LABP) Short Interest UpdateLandos Biopharma, Inc. (NASDAQ:LABP - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.April 3, 2024 | marketbeat.comLandos Biopharma, Inc. Expected to Earn Q1 2024 Earnings of ($0.88) Per Share (NASDAQ:LABP)Landos Biopharma, Inc. (NASDAQ:LABP - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Landos Biopharma in a note issued to investors on Monday, April 1st. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share ofApril 1, 2024 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Landos Biopharma (NASDAQ:LABP)HC Wainwright reiterated a "neutral" rating and set a $20.42 price target (down previously from $50.00) on shares of Landos Biopharma in a report on Monday.March 27, 2024 | businesswire.comLANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPMarch 27, 2024 | finanznachrichten.deLandos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 27, 2024 | markets.businessinsider.comLeerink Partners Remains a Hold on Landos Biopharma (LABP)March 26, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMarch 26, 2024 | markets.businessinsider.comAbbVie To Acquire Landos Biopharma At $20.42/share In CashMarch 26, 2024 | bizjournals.comAbbVie to buy Landos Biopharma for $137 millionMarch 26, 2024 | finance.yahoo.comWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?March 25, 2024 | investorplace.comWhy Is Landos Biopharma (LABP) Stock Up 168% Today?March 25, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieMarch 25, 2024 | businesswire.comLABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to ShareholdersMarch 25, 2024 | reuters.comAbbVie to buy Landos to expand pipeline of immunity-related illnessesMarch 25, 2024 | prnewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 25, 2024 | marketbeat.comTrading was temporarily halted for "LABP" at 08:03 AM with a stated reason of "News pending."March 25, 2024 | globenewswire.comAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesMarch 21, 2024 | investorplace.comLABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023March 21, 2024 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 21, 2024 | benzinga.comRecap: Landos Biopharma Q4 EarningsMarch 21, 2024 | globenewswire.comLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comXontogeny, LLC's Net WorthMarch 5, 2024 | finance.yahoo.comWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?January 10, 2024 | benzinga.comAmbrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis OrganisationNovember 22, 2023 | msn.comLandos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trialNovember 21, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisNovember 21, 2023 | marketwatch.comLandos Biopharma Shares Rise 10% After Positive Trial Data for NX-13November 21, 2023 | finance.yahoo.comLandos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and ColitisNovember 9, 2023 | msn.comLandos Biopharma GAAP EPS of -$0.94November 9, 2023 | benzinga.comLandos Biopharma: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsNovember 1, 2023 | marketbeat.comTrading was temporarily halted for "LABP" at 09:11 AM with a stated reason of "LULD pause."October 23, 2023 | finance.yahoo.comLandos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific MeetingSeptember 22, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Hold Rating for Landos Biopharma (LABP)September 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 19, 2023 | finance.yahoo.comLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressSeptember 14, 2023 | finance.yahoo.comLandos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsAugust 9, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | seekingalpha.comSCPS Scopus BioPharma Inc.August 9, 2023 | finance.yahoo.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 ResultsAugust 9, 2023 | finance.yahoo.comLandos Biopharma Provides Business Update & Reports Second Quarter 2023 Results Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of cash before the Fed's next meeting (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview LABP Media Mentions By Week LABP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LABP News Sentiment▼0.000.62▲Average Medical News Sentiment LABP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LABP Articles This Week▼01▲LABP Articles Average Week Get Landos Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Achilles Therapeutics News Aspira Women's Health News TherapeuticsMD News Sensei Biotherapeutics News Adverum Biotechnologies News Foghorn Therapeutics News Nektar Therapeutics News Mersana Therapeutics News Eliem Therapeutics News CorMedix News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LABP) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Landos Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Landos Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
